chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Rash/Rash extended to chest and down to stomach; Rash and pain at injection site; Rash and pain at injection site; Significant swelling in armpit with warmth; Significant swelling in armpit with warmth; pain; Swelling of lymph nodes under arm and into chest. All on L arm side where injection was administered; Significant fatigue for 4 days following; This is a spontaneous report from a contactable contactable Other-HCP (patient) .  A 37-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection) intramuscular at left arm on 13Jan2021 09:30 AM at SINGLE DOSE for COVID-19 immunization.No pregnant.Medical history included asthma. The patient had COVID prior vaccination .Facility where the most recent COVID-19 vaccine was administered was Living Facility.The patient didn't received any other vaccines within 4 weeks prior to the COVID vaccine. Concomitant medications (received within 2 weeks of vaccination) fexofenadine hydrochloride (ALLEGRA) paracetamol (TYLENOL). On 14Jan2021 16:00  the patient developed  Rash and pain at injection site, rash extended to chest and down to stomach, significant swelling in armpit with warmth and pain, swelling of lymph nodes under arm and into chest. All on Left arm side where injection was administered  and significant fatigue for 4 days following. The adverse events resulted in: Doctor or other healthcare professional office/clinic visit.No treatment received.The events were assessed as non-serious. The patient had been tested for COVID post vaccination on 17Jan2021 (test type = Nasal Swab Covid test name post vaccination= Rapid). The outcome of the events was recovering  Information on lot/batch number has been requested.
Urticaria starting approximately 42-44 hours after injection continuing through the time of this report. She denies any rash, just intense itching.
Pt developed generalized erythematous rash over body about 48 hours, post vax.
Systemic: Confusion-Mild, Systemic: Dizziness / Lightheadness-Mild, Systemic: Exhaustion / Lethargy-Mild, Systemic: Fainting / Unresponsive-Mild, Systemic: Flushed / Sweating-Medium, Systemic: Hypotension-Medium, Systemic: Shakiness-Mild, Additional Details: No immediate reaction after vaccine administration.  He was sweating profusely and momentarily lost consciousness/not responsive.  He came around after a minute or two.  He was shaking, so we got him down onto the floor & had him roll to his left side.  We called the paramedics to check him out.  He was responsive & was answering all questions.  He said that he was tired.  We questioned him about his medication schedule & he said he takes his blood pressure meds in the pm.  He had not eaten.
covid vaccine breakhthrough case  dose 1 Pfizer 12/2/21  FH8027
Yeast infection; This spontaneous case was reported by a consumer and describes the occurrence of FUNGAL INFECTION (Yeast infection) in a 25-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 011021A and 027D21A) for COVID-19 vaccination.     The patient's past medical history included Asthma, Seizures, Anxiety, Arthritis and Bacterial vaginosis. Previously administered products included for Product used for unknown indication: Flu shot. Concurrent medical conditions included Diabetes. Concomitant products included PROCATEROL HYDROCHLORIDE (PRO-AIR), SITAGLIPTIN PHOSPHATE (JANUVIA), GLUCOSE and LEVETIRACETAM (KEPPRA [LEVETIRACETAM]) for an unknown indication.   On 01-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Jul-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 27-Jun-2021, the patient experienced FUNGAL INFECTION (Yeast infection). The patient was treated with METRONIDAZOLE ongoing since an unknown date at an unspecified dose and frequency and ZINC OXIDE (DESITIN [ZINC OXIDE]) ongoing since an unknown date at an unspecified dose and frequency. At the time of the report, FUNGAL INFECTION (Yeast infection) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Glycosylated haemoglobin: a1c was at 9 (abnormal) A1C was at 9 for at least three months to date.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) and mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route), the reporter did not provide any causality assessments.   This case was linked to MOD-2021-253057 (Patient Link).
rash at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE RASH (rash at the injection site) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. unknown) for COVID-19 vaccination.     No medical history was provided by the reporter.     On 30-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 30-Mar-2021, the patient experienced VACCINATION SITE RASH (rash at the injection site). At the time of the report, VACCINATION SITE RASH (rash at the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were provided by the reporter. Treatment information was not provided.
March 1st I got sick and thought I had the flu or COVID. Diarrhea, fever, chills for 10 days. I had a COVID test and it was negative. I isolated for 14 days in case. March 3,  I had a doctor Televisit call and was taking Tylenol for the fever and got cough syrup.
Confusion, Dizziness, Headache, Sedation, NauseaVomiting, PAIN 5 OF 10, CHILLS Narrative:
Patient felt light headed and nauseous approx. 1 minute  after receiving vaccine.  Patient never lost consciousness. Patient requested EMS assistance and was transported to hospital by EMS..  Patient disclosed to EMS that she has been in hospital  with similar symptoms earlier in the day, which she failed to disclose to administering  pharmacist.  Patient reviewed and signed VIS form prior to injection and answered "no" to questions about feeling sick or injured.
Developed cough 4 hours after vacation then started to have shortness of breath, went to ER, received prednisone.
I was 1 month postpartum at the time of my vaccine and lactating/nursing my 4 week old. I became feverish and had the chills the night of the vaccine and noticed several milk ducts/veins in my left breast (the same side I got the vaccine)  were severely inflamed and very painful and red.  This side effect resolved over 2 days.
Right eye crossing uncontrollably constant-variable nystagmus 10/24/07 at ophthmologist-continued by neurologist.
ACUTE HYPOXEMIC RESPIRATORY FAILURE 12/29/2022 DYSPNEA CHRONIC HYPOXEMIC RESPIRATORY FAILURE 10/31/2022 DYSPNEA RESPIRATORY FAILURE, UNSPECIFIED ACUITY 11/21/2022 DYSPNEA ACUTE HYPOXEMIC RESPIRATORY FAILURE 12/29/2022 CHF EXACERBATION, UNSPECIFIED CHRONIC HYPOXEMIC RESPIRATORY FAILURE 10/31/2022 CHF EXACERBATION, UNSPECIFIED RESPIRATORY FAILURE, UNSPECIFIED ACUITY 11/21/2022 CHF EXACERBATION, UNSPECIFIED ACUTE HYPOXEMIC RESPIRATORY FAILURE 12/29/2022 AV BLOCK, MOBITZ TYPE 2 CHRONIC HYPOXEMIC RESPIRATORY FAILURE 10/31/2022 AV BLOCK, MOBITZ TYPE 2 RESPIRATORY FAILURE, UNSPECIFIED ACUITY 11/21/2022 AV BLOCK, MOBITZ TYPE 2 ACUTE HYPOXEMIC RESPIRATORY FAILURE 12/29/2022 SYSTOLIC HEART FAILURE, CHRONIC CHRONIC HYPOXEMIC RESPIRATORY FAILURE 10/31/2022 SYSTOLIC HEART FAILURE, CHRONIC RESPIRATORY FAILURE, UNSPECIFIED ACUITY 11/21/2022 SYSTOLIC HEART FAILURE, CHRONIC ACUTE HYPOXEMIC RESPIRATORY FAILURE 12/29/2022 SYSTOLIC HEART FAILURE, CHRONIC CHRONIC HYPOXEMIC RESPIRATORY FAILURE 10/31/2022 SYSTOLIC HEART FAILURE, CHRONIC RESPIRATORY FAILURE, UNSPECIFIED ACUITY 11/21/2022 SYSTOLIC HEART FAILURE, CHRONIC
The pt developed right upper thigh cellulitis which was noted one week post vax. The pt was hospitalized for 2 days for IV antibiotics then changed to p.o. Doing well, no abscess noted.
Scheduled the first available appointment to get the vaccine outside the recommended timeframe; Scheduled the first available appointment to get the vaccine outside the recommended timeframe; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT ADMINISTRATION INTERRUPTED (Scheduled the first available appointment to get the vaccine outside the recommended timeframe) and PRODUCT AVAILABILITY ISSUE (Scheduled the first available appointment to get the vaccine outside the recommended timeframe) in a 51-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT ADMINISTRATION INTERRUPTED (Scheduled the first available appointment to get the vaccine outside the recommended timeframe) and PRODUCT AVAILABILITY ISSUE (Scheduled the first available appointment to get the vaccine outside the recommended timeframe). At the time of the report, PRODUCT ADMINISTRATION INTERRUPTED (Scheduled the first available appointment to get the vaccine outside the recommended timeframe) and PRODUCT AVAILABILITY ISSUE (Scheduled the first available appointment to get the vaccine outside the recommended timeframe) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant and treatment medications were reported.  For mRNA-1273 (Moderna COVID-19 Vaccine) (unknown), the reporter did not provide any causality assessments.
Localized pain and redness (L) shoulder, fatigue. (L) bicep pain. TX: topical steroids, ice.
Muscular pain in left arm where injection was received. Pain radiated outwards towards arm and left pectoral muscle; Muscular pain in left arm where injection was received. Pain radiated outwards towards arm and left pectoral muscle/ I occasionally feel pain in my left pectoral muscle.; Joint pain was also present in the shoulder area; Muscular pain in left arm where injection was received. Pain radiated outwards towards arm and left pectoral muscle.; The patient received third/booster dose of BNT162b2; BNT162b2 was administered on same day when influenza vaccine was administered; This is a spontaneous report from a non-contactable consumer, the patient. A 32-year-old male patient received third (booster) dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FG3527) via an unspecified route of administration in the left arm on 27Oct2021 at 10:00 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. The patient also received influenza vaccine (MANUFACTURER UNKNOWN; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 27Oct2021, as single dose for immunization. The patient did not have any medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any medications within two weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6206) via an unspecified route of administration in the left arm on 06Mar2021 at 16:00 (at the age of 32-years-old) and second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in the left arm on 27Mar2021 at 16:00 (at the age of 32-years-old) as single doses for COVID-19 immunisation. On 27Oct2021 at 11:00, the patient experienced muscular pain in left arm where injection was received. The pain radiated outwards towards arm and left pectoral muscle. Joint pain was also present in the shoulder area. This was lasted about 7-10 days before the pain started to subside. As of 10Nov2021, the patient occasionally felt pain in left pectoral muscle. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events muscular pain in left arm where injection was received, joint pain present in the shoulder area and pain radiated outwards towards arm and left pectoral muscle/feel pain in left pectoral muscle were resolving at the time of this report.    No follow-up attempts are possible. No further information is expected.
rheumatoid arthritis flare/covid booster seemed to send into flare; Booster; This is a solicited report from a contactable consumer (patient) based on information received by Pfizer.   A 57-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), dose 3 intramuscular in 2021 (Batch/Lot number was not reported) as dose 3 (booster), single for covid-19 immunisation at the age of 57-year-old; adalimumab (HUMIRA, 40MG/0.4ML, Solution for injection in pre-filled pen), via subcutaneous from Jan2021 (Batch/Lot number was not reported) to an unspecified date, at 40 mg (40 mg,1 in 14 D) for rheumatoid arthritis.  The patient medical history was not reported. It was unknown if she was enrolled in a COVID-19 Vaccine Trial. Concomitant medications included hydroxychloroquine sulfate; venlafaxine hydrochloride (EFFEXOR SR); metoprolol tartrate; vitamin d3; metformin hcl; levothyroxine sodium (SYNTHROID); Olmesartan Medoxomil (BENICAR); acetylsalicylic acid (ASPIRIN COX); ezetimibe (ZETIA); eicosapentaenoic acid ethyl ester (VASCEPA). She previously received first dose and second dose COVID-19 Vaccine manufactured by Pfizer (BNT162B2), via intramuscular for covid-19 immunisation in 2021. She received booster dose COVID-19 vaccine manufactured by Pfizer. In Oct2021, the patient experienced rheumatoid arthritis flare/covid booster seemed to send into flare. The action taken in response to the events for adalimumab was unknown. In Oct2021, the rheumatoid arthritis flare/covid booster seemed to send into flare resolved.  The reporter's assessment of the causal relationship of the events with the bnt162b2 was not provided at the time of this report. Since no determination has been received, the case is managed based on the company causality assessment.  Causality for adalimumab: The reporter's causality for the event of rheumatoid arthritis flare/covid booster seemed to send into flare was probable.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Based on known drug safety profile, there is reasonable possibility of causal association between the event Rheumatoid arthritis and BNT162B2.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.
within minutes after shot, patient got dizzy, light-headed, nauseous, arms tingled, had impending sense of doom; symptoms resolved after 20 minutes
received the first Shingrix dose in Mar-2020  / she has yet to receive the second Shingrix; was given the Shingrix dose in the butt and not her arm; made her sick for a week; This case was reported by a consumer via call center representative and described the occurrence of sickness in a elderly female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   In March 2020, the patient received the 1st dose of Shingrix. On an unknown date, the patient received the 2nd dose of Shingrix. In March 2020, unknown after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced vaccine administered at inappropriate site. On an unknown date, the patient experienced sickness and incomplete course of vaccination. On an unknown date, the outcome of the sickness was recovered/resolved and the outcome of the vaccine administered at inappropriate site and incomplete course of vaccination were unknown.   It was unknown if the reporter considered the sickness to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported but could be 73 or 74 years for the 1st dose. The age at vaccination was not applicable for the 2nd dose. Till the time of reporting, the patient did not receive the 2nd dose of Shingrix because of what hapenned with the 1st dose, which led to incomplete course of vaccination. The patient received the 1st dose in the butt and not her arm, which led to  vaccine administered at inappropriate site. The patient stated that, the 1st dose made her sick for a week. The patient was unable to provide the dosage as well as lot number and expiration date for the Shingrix dose. The patient declined to provide her date of birth, address, phone number or any other contact information. The reporter did not consent to follow up.
Immediately after the first shot felt severe fatigue and brain fog. The fatigue lasted about two months and the brain fog is persisting to present day.
Patient felt shaky and fainted but still remain conscious. I ran out to put patient on the floor and monitor her condition closely. i kept asking her if she has trouble of breathing and she said that she's OK while my tech had already called the 911 for help. 5 minutes later the paramedic arrived and performed vital checks on her. they said she's ok nothing wrong with her so she doesn't need to go to the hospital for any  further check up.
Tingling in face, extreme swelling at injection sight (about the size of a baseball), redness and hot to the touch.  Later, fever, chills, and severe aches and pains lasting for 42 hours.  Slight fever and lingering swelling and heat radiating from injection site.
Within a couple of hours of vaccination, patient began to experience throat pain and swelling, pruritis, fever/chills, and nausea/vomiting.  Over the course of a couple of hours, the symptoms subsided a little; patient was treated with Benadryl.
Mom describes baseball size area on Left arm at site of Varivax injection. Red and warm. Ice and Advil per doctor. Seen 11/16/06 in Urgent Care.  Prescribed Keflex 500mg cap every 10hours for 10days.
I began to have aphasia on the 28th of October, for about 3 minutes, no visual lossy, was tested for strength and visual in office during Doctor visit and nothing seemed to be an issue.
very bad reaction; diarrhea; 104 temp; chills; vomiting; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION COMPLICATION (very bad reaction), DIARRHOEA (diarrhea), PYREXIA (104 temp), CHILLS (chills) and VOMITING (vomiting) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (very bad reaction), DIARRHOEA (diarrhea), PYREXIA (104 temp), CHILLS (chills) and VOMITING (vomiting). At the time of the report, VACCINATION COMPLICATION (very bad reaction), DIARRHOEA (diarrhea), PYREXIA (104 temp), CHILLS (chills) and VOMITING (vomiting) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 104 (High) 104 temp chills.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported. No treatment medications were reported.
Tachycardia, diaphoresis, headache, neck pain, muscle aches, fatigue. Everything but fatigue lasted approx 12 hours, fatigue about 4 days.
Low grade headache/dizziness/cobwebs still 10 days after vaccine - always there but sometimes barely feel, sometimes stonger
Upper right arm swollen,; skin hot; skin hot and red; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 09Apr2021 at 10:30(at the age of 61-year-old) as a single dose for COVID-19 immunisation. Medical history included diabetes, hypertension and stroke. The patient received medication(unspecified) within two weeks of vaccination. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 19Mar2021 at 10:30(at the age of 61-year-old) as a single dose for COVID-19 immunisation. The patient had no known allergies.  Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 10Apr2021, the patient experienced upper right arm swollen, skin hot and red. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the event upper right arm swollen, skin hot and red was not recovered at this time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Swollen lymph gland; This case was reported by a other health professional via interactive digital media and described the occurrence of enlargement of lymph nodes in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix at an unknown dose. On an unknown date, unknown after receiving Shingrix, the patient experienced enlargement of lymph nodes. On an unknown date, the outcome of the enlargement of lymph nodes was unknown.   It was unknown if the reporter considered the enlargement of lymph nodes to be related to Shingrix.  Additional information was provided as follows: The age at vaccination was not reported. The age group was captured as an adult as per vaccine indication. The patient experienced swollen lymph gland after receiving Shingrix vaccine.
He had fever to 100.5 and fussiness on 10/22/17. Rash started 10/23/17 on back, across abdomen, left arm and right leg. Rash is described as red with irregular wheals of various sizes. Rash completely resolved on 10/26/17. He only had one day of low grade fever 10/22/17.